Array BioPharma

NASDAQ: ARRY
Tuesday's top analyst calls from Wall Street include CBOE, Comcast, GW Pharmaceuticals, Hormel Foods, Vonage and Wells Fargo.
Jon C. Ogg
24/7 Wall St. has picked out some of the major companies in the health care sector that are moving ahead of the first presidential debate and added in some color for each.
Chris Lange
One category of analyst calls that often comes with great upside is in the small-cap and low-priced stocks. Some of these stocks trade under $10 per share.
Chris Lange
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
Chris Lange
What most investors are looking for is a solid solution in what is a confusing market. So we have compiled a list of a few biotech companies that fit the bill, and analysts are saying they can fill...
Chris Lange
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in September.
Chris Lange
Shares of Array BioPharma saw a handy gain in Tuesdays session following the announcement of mid-stage results from its cardiomyopathy trial.
Chris Lange
The top analyst upgrades, downgrades and initiations seen on Monday morning include Harley-Davidson, HP, KeyCorp, KLA-Tencor, Netflix, Square and T-Mobile.
Jon C. Ogg
The broad markets are continuing to hit all-time highs as the market is shifting gears out of the earnings season. Despite all the positive sentiment in the market, quite a few companies still...
Chris Lange
The analysts at Stifel have noted three biotech companies that not only have data that could prove to be huge, but also have stocks that have been absolutely hammered over the past year.
Lee Jackson
Array BioPharma Inc. (NASDAQ: ARRY) is watching its shares make a handy gain on Friday after making a key U.S. Food and Drug Administration (FDA) submission. The company announced the submission of a...
Chris Lange
Array BioPharma reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial.
Chris Lange
While the late summer doldrums are here, the insider action since the end of the second-quarter earnings season is hardly dull.
Lee Jackson
Among speculative small-cap biotechs, analyst calls are often accompanied with upside price targets of 50%, 100% or even 200%. This is because the companies are often all-in bets on one or two...
Jon C. Ogg
Array BioPharma released disappointing fiscal third-quarter earnings before the markets opened Monday morning.
Chris Lange